Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for women with metastatic breast cancer. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to women age 18 and older 
  • Diagnosed with metastatic breast cancer 
  • Detailed eligibility will be reviewed when you contact the study team

This clinical trial is for men and women with non-Hodgkin lymphoma, Richter's syndrome, chronic lymphocytic leukemia (CLL)/ small lymphocytic leukemia (SLL), T-cell lymphoma, multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrom

Key Inclusion / Exclusion Criteria:

   • Men and women between the ages of 18 and 85 
   • Diagnosis of non-Hodgkin lymphoma (NHL), Richter's syndrome, chronic lymphocytic leukemia (CLL), T-cell lymphoma, multiple myeloma (MM), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS) that is relapsed/refractory after at least two lines of therapy, and no standard of care exists. 
   • Must have failed to achieve a response or have recurrent disease after previous treatment 
   • Detailed eligibility reviewed when you contact the study team 

This is a Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial.

Key Inclusion / Exclusion Criteria:
  • Open to men and women 18 years of age and older currently participating in an Astellas-sponsored ASP2215 trial, receiving ASP2215 and able to enroll in this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug.
  • Subject must be deriving benefit from continued treatment as determined by the Investigator. 

Detailed eligibility criteria will be reviewed by the study team.

This clinical trial is for patients with locally advanced or metastatic urothelial cancer.

Key Inclusion / Exclusion Criteria:
  • Adults 18 Years and older 
  • Diagnosis of locally advanced or metastatic urothelial cancer 
  • Eligible for CPI therapy and must be either ineligible for first-line cisplatin-based chemotherapy 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is open to men age 18 or older who have metastatic prostate cancer to check safety and tolerability of ZEN003694 in combination with enzalutamide. 

Key Inclusion / Exclusion Criteria:
  • Open to men 18 years or older 
  • With metastatic, castrate resistant, confirmed prostate cancer (surgically castrated or continuous medical castration for ≥ 8 weeks prior to screening). 
  • Detailed eligibility reviewed when you contact the study team 

This clinical trial is for men and women with advanced urothelial cancer. The purpose of this study is to research the effects (both good and bad) of two investigational drugs called erdafitinib and JNJ-63723283.

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older 
  • Urothelial cancer with specific gene mutations 
  • Previous treatment for metastatic disease (disease which has spread to other parts of the body) 
  • Detailed eligibility reviewed when you contact the study team 

This is a Phase 1b/2 study for men and women with a myeloid neoplasm: myelodysplastic syndrome (MDS), a myeloproliferative neoplasm (MPN), or chronic myelomonocytic leukemia (CMML), who are positive for a TP53 mutation. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women age 18 years or older with a diagnosis of myelodysplastic syndrome (MDS), MDS/ myeloproliferative neoplasm (MPN) or chronic myelomonocytic leukemia (CMML) 
  • Documentation of a TP53 gene mutation by next-generation sequencing (NGS) 
  • Detailed eligibility reviewed when you contact the study team. 

The primary objective of this trial is to evaluate the effectiveness and safety of IMMU-13 in men and women with bladder cancer

Key Inclusion / Exclusion Criteria:
  • Women and men 18 and older who have been diagnosed with bladder cancer 
  • Prior therapies:
    - Cohort 1: have had progression or recurrence of bladder cancer following receipt of platinum- containing regimen (cisplatin or carboplatin) and anti-PD-1/anti-PD-L1 therapy. 
    - Cohort 2: have had progression or recurrence of bladder cancer after a first-line therapy for metastatic disease. 
  • Detailed eligibility reviewed when you contact the study team. 

This clinical trial is open to women and men age 18 and older with previously treated mantle cell lymphoma (MCL).

Key Inclusion / Exclusion Criteria:
  • Women and men age 18 and older
  • Diagnosis of mantle cell lymphoma (MCL) who have received at least one prior systemic therapy 
  • Detailed eligibility reviewed when you contact the study team 

    

This clinical trial is for men and women age 18 and older with B-cell non-follicular indolent non-Hodgkin’s lymphoma. Relapsed and refractory indolent non-Hodgkin’s lymphomas are difficult to treat with poor overall response rate and overall survival. 

Key Inclusion / Exclusion Criteria:
  • Men and women age 18 and older. 
  • Histologically confirmed diagnosis of B-cell non-follicular indolent non-Hodgkin’s lymphoma, including Waldenstrom’s macroglobulinemia. 
  • Relapsed or refractory after at least one prior treatment regimen, with no limit on prior therapies. 
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.